***Background.*** Isavuconazole (ISA) is a novel, water-soluble, broad-spectrum triazole antifungal available in IV and oral formulations for treatment of invasive fungal disease. A Phase 3 trial (NCT00412893) assessed the efficacy and safety of ISA vs. voriconazole (VRC) in patients with invasive mold disease (IMD). Here we report on a pre-specified subset of patients from this trial who had proven/probable invasive aspergillosis (IA) (EORTC/MSG criteria) and received ≥1 dose of the study drug.

***Methods.*** Patients were randomized 1:1 to receive ISA or VRC for up to 84 days. Dosing regimens were: ISA 200mg IV TID for 2 days, followed by 200mg QD (IV or PO); VRC 6mg/kg IV BID on Day 1, 4mg/kg IV BID on Day 2, then either 4mg/kg IV BID or 200mg PO BID. The primary efficacy endpoint was all-cause mortality (ACM) through Day 42. Overall success at end of treatment (EOT) and safety were also assessed. All diagnoses and outcomes were assessed by an independent, blinded, data-review committee. Safety data are presented as reported by the Investigator.

***Results.*** Overall 231 patients were included in this analysis (ISA n = 123; VRC n = 108). Patient characteristics, efficacy, and safety outcomes are shown in the table. Differences in drug-related AEs between ISA and VRC were statistically significant (p \< 0.001).

###### 

Patient characteristics and outcomes

                                                  **ISA (n=123)**    **VRC (n=108)**
  --------------------------------------------- ------------------- -----------------
  *Patient characteristics*                                         
  Age (years), mean±SD                                 51±16              52±15
  Male, n (%)                                         69 (56)            71 (66)
  Primary underlying condition, n (%)                               
   Acute myeloid leukemia                             44 (36)            47 (44)
   Acute lymphocytic leukemia                         15 (12)             9 (8)
   Non-Hodgkin\'s lymphoma                            14 (11)             2 (2)
  Other                                               49 (40)            49 (45)
  *Outcome--Efficacy*                                               
  ACM on Day 42, n (%)                                23 (19)            24 (22)
   Adjusted difference (ISA--VRC), % (95% CI)    −2.7 (−12.9, 7.5)  
  ACM on Day 84                                       35 (29)            39 (36)
   Adjusted difference (ISA--VRC), % (95% CI)    −5.7 (−17.1, 5.6)  
  Overall success at EOT, n (%)                       43 (35)            42 (39)
   Adjusted difference (VRC--ISA), % (95% CI)    4.0 (−8.0, 15.9)   
  *Outcome--Safety, n (%)*                                          
  AEs                                                118 (96)           106 (98)
  Drug-related AEs                                    48 (39)            67 (62)
  Serious AEs                                         71 (58)            71 (66)
  Drug-related serious AEs                            16 (13)            13 (12)
  AEs leading to discontinuation                      22 (18)            26 (24)

***Conclusion.*** In patients with documented IA, ISA had comparable efficacy to VRC, but was better tolerated than the latter.
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